AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05296850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Release
Description: Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
Study NCT05296850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension.
Study NCT06168318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.
Study NCT06168318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation E
Description: Oral administration of VH4004280 Formulation E in fasted or fed conditions.
Study NCT05082714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
Study NCT05082714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
Study NCT06028984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention app
Description: An app-based intervention for depression
Study NCT06028984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control app
Description: An app with non-therapeutic content
Study NCT04906954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NMES
Description: Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
Study NCT00012740 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Casefinding and Referral System
Study NCT05728970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LumiraDx SARS-CoV-2 Ag Ultra
Description: The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
Study NCT05728970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LumiraDx SARS-CoV-2 & Flu A/B
Description: The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
Study NCT05006092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOMIND
Description: CADe system for Polyp detection
Study NCT06369649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coolsense and Buzzy
Description: Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
Study NCT06389916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology MAX (current design)
Description: The current lens design
Study NCT06389916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology MAX Phoenix (new design)
Description: The new lens design
Study NCT06049732 — intervention group
Intervention type: DEVICE
Intervention: PainChek®
Description: Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
Study NCT06383442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-HIIT
Description: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)
Study NCT06383442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-HIIT
Description: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
Study NCT06674122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral vitamin D supplementation of 800 IU/day
Description: Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
Study NCT06674122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral vitamin D supplementation of 400 IU/day
Description: Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
Study NCT06676514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Butirrisan®
Description: Probiotic Clostridium butyricum CBM588®
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICF
Description: Application of Informed Consent Form.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICF
Description: Application of Informed Consent Form.
Study NCT06676410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eligibility Assessment
Description: Assessment of inclusion, exclusion and discontinuation criteria.
Study NCT06676410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility Assessment
Description: Assessment of inclusion, exclusion and discontinuation criteria.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demographic data
Description: Collection of demographic data.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic data
Description: Collection of demographic data.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Weight, height and BMI
Description: Weight and height measurement and body mass index calculation.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Weight, height and BMI
Description: Weight and height measurement and body mass index calculation.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vital Signs
Description: HR, BP and FR and T°, in addition to oximetry.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: HR, BP and FR and T°, in addition to oximetry.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical evaluation
Description: Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Medical evaluation
Description: Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety exam
Description: Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Safety exam
Description: Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: β-HCG in urine in non-sterile women
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: β-HCG in urine in non-sterile women
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serology
Description: HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serology
Description: HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization
Description: Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomization
Description: Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Apoptosis markers
Description: Caspases and Annexin V.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apoptosis markers
Description: Caspases and Annexin V.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cell activation markers
Description: PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cell activation markers
Description: PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation markers
Description: ultrasensitive CRP, D-dimer.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inflammation markers
Description: ultrasensitive CRP, D-dimer.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Proviral DNA:
Description: Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Proviral DNA:
Description: Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV-specific antibodies
Description: Anti-HIV-1 specific antibody titers in plasma.
Study NCT05297422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm surgey
Description: Microsurgery Clinic , KAT Hospital Athens
Study NCT05686148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
Study NCT04916483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group cognitive stimulation therapy
Description: The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
Study NCT05297422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine
Study NCT04916483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: The control group maintains the unit routine treatment.
Study NCT05297422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine
Study NCT06518512 — intervention group
Intervention type: DEVICE
Intervention: Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system
Description: AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit
Study NCT06554834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CV4 + RR
Description: Participants in this group will undergo three 30-minute sessions of osteopathic therapy. The intervention will involve a combination of the Fourth Ventricle Compression (CV4) technique and the Rib Raising (RR) technique. These sessions will be administered once per week over three consecutive weeks. The CV4 technique involves gentle compression of the occiput to influence cranial rhythmic impulses, while the RR technique involves mobilization of the rib cage to impact autonomic nervous system function.
Study NCT06554834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CV4
Description: Participants in this group will receive three 30-minute sessions focusing solely on the Fourth Ventricle Compression (CV4) technique. The sessions will be conducted once per week for three consecutive weeks. The CV4 technique involves applying gentle pressure to the occiput with the goal of affecting cranial rhythmic impulses and promoting autonomic nervous system balance.
Study NCT06554834 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham ultrasound transducer
Description: Participants in the placebo group will undergo three 30-minute sessions of a sham procedure using an ultrasound transducer. The transducer will be applied in a manner that mimics a therapeutic intervention, but without delivering any actual therapeutic effect. These sessions will also be conducted once per week for three consecutive weeks.
Study NCT06554834 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Transducer Sham Procedure
Description: Participants in the placebo group will undergo three 30-minute sessions using an ultrasound transducer as part of a sham procedure. The transducer will be applied to the body in a manner that mimics a therapeutic intervention, but it will not deliver any actual therapeutic effect. This procedure is designed to simulate the experience of receiving treatment without providing the physiological benefits associated with active ultrasound therapy. The sessions will be conducted once per week over three consecutive weeks.
Study NCT06554834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System
Description: Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
Study NCT06554834 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System
Description: Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV-specific antibodies
Description: Anti-HIV-1 specific antibody titers in plasma.
Study NCT06400836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate timing - carbohydrate intake before or after exercise
Description: The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
Study NCT06400836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate timing - carbohydrate intake before or after exercise
Description: The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
Study NCT06393595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: surface enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation.
Study NCT04551573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine daily
Description: In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
Study NCT04551573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine weekly
Description: In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
Study NCT05605379 — intervention group
Intervention type: BIOLOGICAL
Intervention: Next Generation Sequencing (DNA and RNA)
Description: Targeted Next Generation Sequencing (DNA and RNA)
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV viral load (RNA)
Description: Performed on plasma.
Study NCT06676410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV viral load (RNA)
Description: Performed on plasma.
Study NCT06676410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Codivir® Training
Description: The participant is trained to self-inject Codivir®
Study NCT06676410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispensing Codivir®
Description: the participant receives Codivir®
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Codivir® Accounting
Description: The Codivir® used since the last visit is accounted for